KR927003529A - (1, 2n) 및 (3, 2n)-카보사이클릭-2-아미노테트랄린 유도체 - Google Patents

(1, 2n) 및 (3, 2n)-카보사이클릭-2-아미노테트랄린 유도체 Download PDF

Info

Publication number
KR927003529A
KR927003529A KR1019920700056A KR920700056A KR927003529A KR 927003529 A KR927003529 A KR 927003529A KR 1019920700056 A KR1019920700056 A KR 1019920700056A KR 920700056 A KR920700056 A KR 920700056A KR 927003529 A KR927003529 A KR 927003529A
Authority
KR
South Korea
Prior art keywords
hexahydro
benz
methoxy
cis
propenyl
Prior art date
Application number
KR1019920700056A
Other languages
English (en)
Other versions
KR0151699B1 (ko
Inventor
린 치우-흥
Original Assignee
로버트 에이, 아미테이지
디 업존 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 로버트 에이, 아미테이지, 디 업존 캄파니 filed Critical 로버트 에이, 아미테이지
Publication of KR927003529A publication Critical patent/KR927003529A/ko
Application granted granted Critical
Publication of KR0151699B1 publication Critical patent/KR0151699B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/08—Aza-anthracenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/10—Aza-phenanthrenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

내용 없음

Description

(1, 2N) 및 (3, 2N)-카보사이클릭-2-아미노테트랄린 유도체
[도면의 간단한 설명]
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (6)

  1. 하기 일반식(I)의 화합물.
    상기식에서, Y는 수소 또는 할로겐이고; R1은 (a) -수소 (b) -OR4(c) -SR4(d) -OSO2CF3(e) -CONR6R6또는 (f) -CO-(2-피롤릴)이며; A는 하기 일반식(a) 또는 (b)이고,
    이때, R2는 (a) - 수소, (b) -(C1-C8)알킬 (c) -(C3-C8)알케닐 (d) -(C3-C8)알키닐 (e) -(CH2)m -(C3-C8)사이클로알킬 (f) -(CH2)m-(C3-C8)사이클로알케닐 (i) -(CH2)m-아릴 또는 (h) -(CH2)m- CO2R6이고, R3는 (a) -수소 (b) -(C1-C4)알킬 (c) -아릴 (d) -(CH2)n-CO(C1-C4)알킬 또는 (e) -CO-아릴이며, R4및 R5는 (a) - 수소, (b) -(C1-C4)알킬 (c) -(C2-C4)알케닐 또는 (d) -아릴이고, R6는 (a) -수소 (b) -(C1-C4)알킬 또는 (c) -아릴이며, m은 1 내지 4이고, n은 0 내지 3이다.
  2. 제1항에 있어서, 하기 일반식(Ia)을 갖는 화합물.
    상기식에서, R1, R2및 R5는 제1항에서와 같다.
  3. 제2항에 있어서, (2α, 3aα, 9bα)-2,3,3a,4,5,9b-헥사하이드로-9-메톡시-2-메틸-3-프로필-1H-벤즈[e]인돌 염산염; (2α,3aβ,9bβ)-2,3,3a,4,5,9b-헥사하이드로-9-메톡시-2-메틸-3-프로필-1H-벤즈[e]인돌 염산염; (2α, 3aα, 9bα) -2,3,3a,4,5,9b-헥사하이드로-2-메틸-3-프로필-1H-벤즈[e]인돌-9-올 염산염; (2α, 3aα, 9bα)-2,3,3a, 4, 5, 9b-헥사하이드로-2-메틸-3-(2-프로페닐)-1H-벤즈[e]인돌-9-올 염산염; 시스-1,2,3,4,4a,5,6,10b-옥타하이드로-10-메톡시-4-(2-프로페닐)-1H-벤즈[f]퀴놀린 염산염; 시스-2,3,3a,4,5,9b-헥사하이드로-9-메톡시-3-(2-프로페닐)-1H-벤즈[e]인돌 염산염; (2α,3aα,9bα)-2,3,3a,4,5,9b-헥사하이드로-2-메틸-3-프로필-1H-벤즈[e]인돌 염산염; 시스-2,3,3a,4,5,9b-헥사하이드로-6-메톡시-3-(2-프로페닐)-벤즈[e]인돌 염산염; 트란스-2,3,3a,4,5,9b-헥사하이드로-6-메톡시-3-(2-프로페닐)-프로필-1H-벤즈[e]인돌 염산염; 시스-2,3,3a,4,5,9b-헥사하이드로-6-메톡시-3-1H-벤즈[e]인돌 염산염; 시스-2,3,3a,4,5,9b-헥사하이드로-3-(2-프로페닐)-1H-벤조[e]인돌 염산염; 시스-1,2,2a,3,4,8b-헥사하이드로-8-메톡시-2-(프로프-2-앤-1-일)-나프토[2.1.B]-아제티딘 염산염; 시스-1,2,2a,3,4,8b-헥사하이드로-2-n-프로필나프토[2.1.B]-아제티딘 염산염; 시스-2,3,3a.4,5,9b-헥사하이드로-9-메톡시-1H-벤즈[e]인돌 염산염; 시스-(1S,2R)-2,3,3a,4,5,9b-헥사하이드로-6-메톡시-3-(2-프로페닐)-1H-벤즈[e]인돌 염산염; 및 시스-(1R,2S)-2,3,3a,4,5,9b-헥사하이드로-6-메톡시-3-(2-프로페닐)-1H-벤즈[e]인돌 염산염으로 이루어진 그룹중에서 선택된 화합물.
  4. 제3항에 있어서, 시스-2,3,3a,4,5,9b-헥사하이드로-6-메톡시-3-(2-프로페닐)-1H-벤즈[e]인돌 염산염; 트란스-2,3,3a,4,5,9b-헥사하이드로-6-메톡시-3-(2-프로페닐)-1H-벤즈[e]인돌 염산염; 시스-2,3,3a,4,5,9b-헥사하이드로-6-메톡시-3-n-프로필-1H-벤즈[e]인돌 염산염; 시스-2,3,3a,4,5,9b-헥사하이드로-3-(2-프로페닐)-1H-벤즈[e]인돌 염산염; 시스-2,3,3a,4,5,9b-헥사하이드로-9-메톡시-3-(2-프로페닐-1H-벤즈[e]인돌 염산염; 시스-1,2,2a,4,5,9b-헥사하이드로-2-n-프로필나프토[2.1.B]-아제티딘 염산염; 시스-2,3,3a.4,5,9b-헥사하이드로-9-메톡시-1H-벤즈[e]인돌 염산염; 시스-(1S,2R)-2,3,3a,4,5,9b-헥사하이드로-6-메톡시-3-(2-프로페닐)-1H-벤즈[e]인돌 염산염; 및 시스-(1R,2S)-2,3,3a,4,5,9b-헥사하이드로-6-메톡시-3-(2-프로페닐)-1H-벤즈[e]인돌 염산염으로 이루어진 그룹중에서 선택된 화합물.
  5. 제1항에 있어서, 하기 일반식(Ib)을 갖는 화합물.
    상기식에서, R1, R2및 R5는 제1항에서와 같다.
  6. 제5항에 있어서, 트란스-2,3,3a,4,9,9b-헥사하이드로-5-메톡시-1-프로필-2H-벤즈[f]인돌 염산염; 시스-2,3,3a,4,9,9b-헥사하이드로-5-메톡시-1-프로필-1H-벤즈[f]인돌 염산염; 트란스-2,3,3a,4,9,9b-헥사하이드로-프로필-1H-벤즈[f]인돌-5-올; 시스-2,3,3a,4,9,9a-헥사하이드로-1-프로필-1H-벤즈[f]인돌-5-올; (2α,3ap,9ap)-2,3,3a,4,9,9a-헥사하이드로-8-메톡시-2-메틸-1-프로필-1H-벤즈[f]인돌 염산염; (2α,3aα,9bα)-2,3,3a,4,5,9b-헥사하이드로-8-메톡시-2-메틸-1-프로필-1H-벤즈[f]인돌 염산염; 시스-2,3,3a,4,5,9b-헥사하이드로-8-메톡시-1-(2-프로페닐)-1H-벤즈[f]인돌 염산염 트란스-2,3,3a,4,9,9b-헥사하이드로-8-메톡시-1-(2-프로페닐)-벤즈[f]퀴놀린 염산염; 트란스-1,2,3,3,4,4a,5,10,10a-헥사하이드로-9-메톡시-2-(2-프로페닐)-1H-벤즈[f]퀴놀린 염산염; 시스-3,4,4a,4,10,10b-헥사하이드로-9-메톡시-1(2-프로페닐)-벤즈[g]-퀴놀린 염산염; 트란스-2,3,3a,4,9,9a-헥사하이드로-5-메톡시-1-(2-프로페닐)-1H-벤즈[f]인돌 염산염; 시스-2,3,3a,4,9,9a-헥사하이드로-5-메톡시-1-(2-프로페닐)-1H-벤즈[f]인돌 염산염; 트란스-(2R, 3R)-2,3,3a,4,9,9a-헥사하이드로-5-메톡시-1-(2-프로페닐)-1H-벤즈[f]인돌 염산염; 및 트란스-(2S, 3S)-2,3,3a,4,9,9a-헥사하이드로-5-메톡시-1-(2-프로페닐)-1H-벤즈[f]인돌 염산염으로 이루어진 그룹중에서 선택된 화합물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019920700056A 1989-07-13 1990-06-27 (1,2n) 및 (3,2n)-카보사이클릭-2-아미노테트랄린 유도체 KR0151699B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37952689A 1989-07-13 1989-07-13
US7/379,526 1989-07-13
PCT/US1990/003551 WO1991000856A2 (en) 1989-07-13 1990-06-27 (1,2n) and (3,2n)-carbocyclic-2-amino tetralin derivatives

Publications (2)

Publication Number Publication Date
KR927003529A true KR927003529A (ko) 1992-12-18
KR0151699B1 KR0151699B1 (ko) 1998-10-15

Family

ID=23497619

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920700056A KR0151699B1 (ko) 1989-07-13 1990-06-27 (1,2n) 및 (3,2n)-카보사이클릭-2-아미노테트랄린 유도체

Country Status (11)

Country Link
US (1) US5491236A (ko)
EP (1) EP0482084B1 (ko)
JP (1) JP3005287B2 (ko)
KR (1) KR0151699B1 (ko)
AT (1) ATE152708T1 (ko)
AU (1) AU648032B2 (ko)
CA (1) CA2057912C (ko)
DE (1) DE69030665T2 (ko)
DK (1) DK0482084T3 (ko)
ES (1) ES2100886T3 (ko)
WO (1) WO1991000856A2 (ko)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486611A (en) * 1989-07-13 1996-01-23 The Upjohn Company Carboxamido-(1,2N)-carbocyclic-2-aminotetralin derivatives
AU639301B2 (en) * 1990-01-11 1993-07-22 Pharmacia & Upjohn Company New centrally acting 6,7,8,9-tetrahydro-3h-benz(e)indole heterocyclics
EP0586553A1 (en) * 1991-05-20 1994-03-16 The Upjohn Company Carboxamido-(3,2n)-carbocyclic-2-aminotetralin derivatives
ES2103374T3 (es) * 1991-05-20 1997-09-16 Upjohn Co Derivados de carboxamido-(1,2n)-carbociclo-2-aminotetralina.
TW239127B (ko) * 1991-12-20 1995-01-21 Hoffmann La Roche
CZ285829B6 (cs) * 1993-06-10 1999-11-17 Eli Lilly And Company Použití derivátu tetrahydrobenz [c,d]indolu pro výrobu farmaceutického prostředku vhodného pro ošetřování sexuální dysfunkce
GB9612153D0 (en) * 1996-06-11 1996-08-14 Smithkline Beecham Plc Compounds
DE19834714A1 (de) * 1998-07-31 2000-02-03 Boehringer Ingelheim Pharma Neue 2,3,3a,4,9,9a-Hexahydro-8-hydroxy-1H-ben[f]indole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
GB0004003D0 (en) * 2000-02-22 2000-04-12 Knoll Ag Therapeutic agents
GB0517292D0 (en) 2005-08-24 2005-10-05 Univ Dundee Cell migration modulating compounds

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1555553A (ko) * 1967-07-05 1969-01-31
US3839338A (en) * 1968-05-09 1974-10-01 W Michne 1,2,3,4,4A,5,10,10A-OCTAHYDROBENZO{8 g{9 QUINOLINES
GB1277789A (en) * 1969-09-08 1972-06-14 Logeais Labor Jacques Improvements in or relating to new polycyclic pyrrole derivatives
JPS4930836B1 (ko) * 1971-07-22 1974-08-16
US4234731A (en) * 1979-01-05 1980-11-18 Bristol-Myers Company 9-Oxobenzomorphan process
US4341786A (en) * 1981-03-02 1982-07-27 Smithkline Corporation Pharmaceutical compositions and method of producing central alpha1 agonist activity utilizing octahydrobenzo[f]quinoline compounds
US4618683A (en) * 1982-06-01 1986-10-21 Abbott Laboratories Tetrahydro-6,7-dimethoxy-1H-benz[e]isoinodolines useful in the treatment of hypertension and as sedatives
PH22782A (en) * 1983-02-01 1988-12-12 Sandoz Ltd Novel pharmaceutical active 1,2,3,4,4a,5,10,10a octahydrobenzo(g)quinoline derivatives
SE8302361D0 (sv) * 1983-04-27 1983-04-27 Astra Laekemedel Ab New tricyclic amines
DE3719924A1 (de) * 1986-12-22 1988-06-30 Bayer Ag 8-substituierte 2-aminotetraline
CA2011640A1 (en) * 1989-03-20 1990-09-20 Rene Imhof Quinoline derivatives
US5244888A (en) * 1989-11-17 1993-09-14 Abbott Laboratories 5-HT selective agents
US5248677A (en) * 1990-03-30 1993-09-28 Abbott Laboratories Biogentic amine uptake inhibitors
US5180733A (en) * 1990-03-30 1993-01-19 Abbott Laboratories Biogenic amine uptake inhibitors
TW239127B (ko) * 1991-12-20 1995-01-21 Hoffmann La Roche

Also Published As

Publication number Publication date
AU6145390A (en) 1991-02-06
ATE152708T1 (de) 1997-05-15
AU648032B2 (en) 1994-04-14
US5491236A (en) 1996-02-13
DE69030665T2 (de) 1997-10-02
KR0151699B1 (ko) 1998-10-15
EP0482084A1 (en) 1992-04-29
EP0482084B1 (en) 1997-05-07
DE69030665D1 (de) 1997-06-12
CA2057912C (en) 1996-10-29
CA2057912A1 (en) 1991-01-14
WO1991000856A3 (en) 1991-03-21
WO1991000856A2 (en) 1991-01-24
DK0482084T3 (da) 1997-11-03
JPH04507408A (ja) 1992-12-24
ES2100886T3 (es) 1997-07-01
JP3005287B2 (ja) 2000-01-31

Similar Documents

Publication Publication Date Title
KR927003529A (ko) (1, 2n) 및 (3, 2n)-카보사이클릭-2-아미노테트랄린 유도체
GT200200084A (es) Sales tartrato de 5, 8,14-triazatetraciclo[10.3.1.0 2,11.0 4,9] hexadeca-2(11),3,5,7,9-pentaeno ycomposicionesfarmaceuticas de las mismas
CA2299113A1 (en) Techniques for mapping graphical user interfaces of applications
DE60312972D1 (de) Produktabgabevorrichtung und träger
KR880005075A (ko) 아제티디논 유도체
ATE382270T1 (de) Verwendung von cubebol als aromastoff
ATE509076T1 (de) Druckverfahren mit essbaren tinten
KR910005416A (ko) 테이프 캐리어 및 그 장착방법 및 장치
DK1123289T3 (da) Oxobenzofuranyliden-dihydroindoloner
EP0232225A3 (de) Epoxidharz-Zusammensetzung
NO890892D0 (no) 1,3,4,5-tetrahydrobenz(c,d)indoler.
DE69624519D1 (de) Ruthenium-Komplex enthaltender Katalysator, seine Verwendung in der Hydrierung ungesättigter Substrate, insbesondere organischer Nitrile
KR910006415A (ko) 열경화성 수지 조성물
GEP20074205B (en) Process for preparing 4-aminodiphenylamine
MXPA03006386A (es) Solucion quimioluminiscente basada en acidos perilen tetracarboxilicos disustituidos, sus dianhidridos y diimidas.
KR920006409A (ko) 방향족 디아민화합물, 그 제조방법 및 이것에서 제조한 폴리이미드
JPH11201398A (ja) ガスホルダのピストン支持構造
TW200504178A (en) Blue luminescence polymer and manufacturing method thereof and luminescence device using the polymer
DE60123105D1 (de) Verfahren zur Herstellung von 4'-O-substituierten 4'-Demethyl-1 desoxypodophyllotoxinderivaten und geometrischen Isomeren davon ,und Antikrebspräparat, das diese enthält
AU2002330445A1 (en) Carrier for bottles and the like
CN213582817U (zh) 一种标牌
KR920001435A (ko) 헤드베이스
Petit Catalogue et propriétés photométriques des étoiles naines rouges à spectre d'émission (dMe)
NO994928D0 (no) Fremgangsmaate ved fremstilling av enkelt-enantiomer narwedine
SU582549A1 (ru) Устройство дл креплени проводов и кабелей

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20040331

Year of fee payment: 7

LAPS Lapse due to unpaid annual fee